1. Home
  2. FUSB vs MAIA Comparison

FUSB vs MAIA Comparison

Compare FUSB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

N/A

Current Price

$16.50

Market Cap

91.4M

Sector

Finance

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.36

Market Cap

79.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FUSB
MAIA
Founded
1952
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
79.0M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
FUSB
MAIA
Price
$16.50
$1.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.7K
443.8K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
1.72%
N/A
EPS Growth
N/A
33.33
EPS
0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.00
$0.87
52 Week High
$16.99
$3.19

Technical Indicators

Market Signals
Indicator
FUSB
MAIA
Relative Strength Index (RSI) 48.94 49.02
Support Level $15.75 $1.24
Resistance Level $16.50 $1.48
Average True Range (ATR) 0.20 0.07
MACD 0.02 0.00
Stochastic Oscillator 21.09 34.83

Price Performance

Historical Comparison
FUSB
MAIA

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: